A new trading day began on Tuesday, with Xilio Therapeutics Inc (NASDAQ: XLO) stock price down -6.20% from the previous day of trading, before settling in for the closing price of $0.84. XLO’s price has ranged from $0.58 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 66.65%. With a float of $14.66 million, this company’s outstanding shares have now reached $43.96 million.
The extent of productivity of a business whose workforce counts for 73 workers is very important to gauge. In terms of profitability, gross margin is 82.23%, operating margin of -852.23%, and the pretax margin is -834.92%.
Xilio Therapeutics Inc (XLO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xilio Therapeutics Inc is 67.95%, while institutional ownership is 15.65%. The most recent insider transaction that took place on Jan 02 ’25, was worth 6,841. In this transaction Chief Financial Officer of this company sold 6,954 shares at a rate of $0.98, taking the stock ownership to the 12,421 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, FINANCE AND ACCOUNTING sold 1,803 for $0.98, making the entire transaction worth $1,774. This insider now owns 3,197 shares in total.
Xilio Therapeutics Inc (XLO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.46% during the next five years compared to -44.91% drop over the previous five years of trading.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Here are Xilio Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.72, a number that is poised to hit 0.19 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
The latest stats from [Xilio Therapeutics Inc, XLO] show that its last 5-days average volume of 0.63 million was inferior to 5.04 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 28.03%. Additionally, its Average True Range was 0.13.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 15.19%, which indicates a significant increase from 14.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.02% in the past 14 days, which was lower than the 189.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9376, while its 200-day Moving Average is $0.9402. Now, the first resistance to watch is $0.8453. This is followed by the second major resistance level at $0.8982. The third major resistance level sits at $0.9563. If the price goes on to break the first support level at $0.7343, it is likely to go to the next support level at $0.6762. The third support level lies at $0.6233 if the price breaches the second support level.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
With a market capitalization of 36.26 million, the company has a total of 43,958K Shares Outstanding. Currently, annual sales are 0 K while annual income is -76,400 K. The company’s previous quarter sales were 2,260 K while its latest quarter income was -14,020 K.
